The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper”
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Despite advancements in medical interventions, the burden of CVD continues to rise due to aging populations, lifestyle factors, and socio-economic disparities. Chronic inflammation plays a pivotal role in CVD pathogenesi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-06-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/187 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849416617236103168 |
|---|---|
| author | Ciarán Kennedy Luke J Conroy Braden Millar Monica de Gaetano |
| author_facet | Ciarán Kennedy Luke J Conroy Braden Millar Monica de Gaetano |
| author_sort | Ciarán Kennedy |
| collection | DOAJ |
| description |
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Despite advancements in medical interventions, the burden of CVD continues to rise due to aging populations, lifestyle factors, and socio-economic disparities. Chronic inflammation plays a pivotal role in CVD pathogenesis, particularly in atherosclerosis, where macrophage polarization influences disease progression. Pharmacological strategies targeting lipid metabolism have evolved beyond statins to include novel therapeutics, such as PCSK9 inhibitors, ezetimibe, and bempedoic acid, offering alternative solutions for statin-intolerant individuals. Precision medicine in CVD harnesses genetic and omics data to personalize risk assessment, guide therapy, and improve outcomes, particularly through targeting genetic variants, inflammation, and clonal haematopoiesis. Additionally, gene-editing technologies, like CRISPR-Cas9, hold promise for addressing genetic contributors to CVD by modulating key regulatory targets, such as PCSK9 and ANGPTL3, potentially providing long-term solutions to hyperlipidaemia. Recent evidence suggests that glucose-lowering medications, including SGLT2 inhibitors and GLP-1 receptor agonists, confer cardiovascular benefits beyond glycaemic control by reducing inflammation, improving endothelial function, and promoting macrophage phenotype switching. Emerging therapies, such as GLP-1/GIP dual agonists, may offer superior cardioprotective effects, but further clinical trials are required to validate their efficacy in CVD. Anti-inflammatory treatments, including IL-1β inhibitors, colchicine, and statins, have demonstrated efficacy in reducing cardiovascular events. However, their broad immunosuppressive effects present challenges. Resolution pharmacology, focusing on specialized pro-resolving lipid mediators (SPMs), represents a novel therapeutic approach aimed at restoring immune balance, in lieu of merely suppressing inflammation. Understanding macrophage-driven inflammation in CVD could revolutionize treatment paradigms, shifting toward targeted interventions that resolve, rather than inhibit, inflammatory processes. Overall, integrating lipid-lowering therapies, gene editing, glucose-modulating drugs, and inflammation-resolution strategies offers a multi-faceted approach to mitigating CVD risk and improving long-term patient outcomes.
|
| format | Article |
| id | doaj-art-1d15aa90b52845a8b56133bd6cbcd887 |
| institution | Kabale University |
| issn | 2785-5309 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Bleeding, Thrombosis and Vascular Biology |
| spelling | doaj-art-1d15aa90b52845a8b56133bd6cbcd8872025-08-20T03:33:08ZengPAGEPress PublicationsBleeding, Thrombosis and Vascular Biology2785-53092025-06-014210.4081/btvb.2025.187The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper”Ciarán Kennedy0https://orcid.org/0000-0003-1967-8754Luke J Conroy1https://orcid.org/0009-0002-9623-3927Braden Millar2https://orcid.org/0009-0003-2485-2953Monica de Gaetano3https://orcid.org/0000-0002-4677-1447UCD Conway Institute and School of Biomolecular and Biomedical School, Diabetes complications Research Centre, University College DublinUCD Conway Institute and School of Biomolecular and Biomedical School, Diabetes complications Research Centre, University College DublinUCD Conway Institute and School of Biomolecular and Biomedical School, Diabetes complications Research Centre, University College DublinUCD Conway Institute and School of Biomolecular and Biomedical School, Diabetes complications Research Centre, University College Dublin Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Despite advancements in medical interventions, the burden of CVD continues to rise due to aging populations, lifestyle factors, and socio-economic disparities. Chronic inflammation plays a pivotal role in CVD pathogenesis, particularly in atherosclerosis, where macrophage polarization influences disease progression. Pharmacological strategies targeting lipid metabolism have evolved beyond statins to include novel therapeutics, such as PCSK9 inhibitors, ezetimibe, and bempedoic acid, offering alternative solutions for statin-intolerant individuals. Precision medicine in CVD harnesses genetic and omics data to personalize risk assessment, guide therapy, and improve outcomes, particularly through targeting genetic variants, inflammation, and clonal haematopoiesis. Additionally, gene-editing technologies, like CRISPR-Cas9, hold promise for addressing genetic contributors to CVD by modulating key regulatory targets, such as PCSK9 and ANGPTL3, potentially providing long-term solutions to hyperlipidaemia. Recent evidence suggests that glucose-lowering medications, including SGLT2 inhibitors and GLP-1 receptor agonists, confer cardiovascular benefits beyond glycaemic control by reducing inflammation, improving endothelial function, and promoting macrophage phenotype switching. Emerging therapies, such as GLP-1/GIP dual agonists, may offer superior cardioprotective effects, but further clinical trials are required to validate their efficacy in CVD. Anti-inflammatory treatments, including IL-1β inhibitors, colchicine, and statins, have demonstrated efficacy in reducing cardiovascular events. However, their broad immunosuppressive effects present challenges. Resolution pharmacology, focusing on specialized pro-resolving lipid mediators (SPMs), represents a novel therapeutic approach aimed at restoring immune balance, in lieu of merely suppressing inflammation. Understanding macrophage-driven inflammation in CVD could revolutionize treatment paradigms, shifting toward targeted interventions that resolve, rather than inhibit, inflammatory processes. Overall, integrating lipid-lowering therapies, gene editing, glucose-modulating drugs, and inflammation-resolution strategies offers a multi-faceted approach to mitigating CVD risk and improving long-term patient outcomes. https://www.btvb.org/btvb/article/view/187Low grade inflammationlipid and glucose metabolismcardiovascular therapeutics |
| spellingShingle | Ciarán Kennedy Luke J Conroy Braden Millar Monica de Gaetano The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper” Bleeding, Thrombosis and Vascular Biology Low grade inflammation lipid and glucose metabolism cardiovascular therapeutics |
| title | The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper” |
| title_full | The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper” |
| title_fullStr | The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper” |
| title_full_unstemmed | The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper” |
| title_short | The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper” |
| title_sort | subtle red line between combating and resolving inflammation in the cardiovascular disease a silent sniper |
| topic | Low grade inflammation lipid and glucose metabolism cardiovascular therapeutics |
| url | https://www.btvb.org/btvb/article/view/187 |
| work_keys_str_mv | AT ciarankennedy thesubtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT lukejconroy thesubtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT bradenmillar thesubtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT monicadegaetano thesubtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT ciarankennedy subtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT lukejconroy subtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT bradenmillar subtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper AT monicadegaetano subtleredlinebetweencombatingandresolvinginflammationinthecardiovasculardiseaseasilentsniper |